"Top Stocks to Buy Right Now"

This is a news story, published by Yahoo Finance, that relates primarily to Iovance Biotherapeutics news.

stocks trading & speculation news

For more stocks trading & speculation news, you can click here:

more stocks trading & speculation news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about

best stocks

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Iovance stock news, Biotech Stock news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

stocks

The Motley Fool

•

Business

Business & Economics

This Biotech Stock Could Be the Best Investment of the Decade

Summary

Nutrition label

75% Informative

Iovance Biotherapeutics is entering a decade of incredible growth.

The biotech company's first -ever drug approval materialized early last year .

Analysts expect revenue to rise by more than 180% , to $762 million , this year , and then grow another 45% to $1.1 billion next year .

The cancer immunotherapy market alone is set to grow at an average annual pace of 10.6% though 2034 .

Shares of Iovance Biotherapeutics are near a new multiyear low, but the sellers don't seem ready or willing to push this ticker below 2023 's low.

This may be a sign that the tide is finally taking a slow turn for the better, reflecting the company's rapidly improving fundamentals.

Despite this stock's lingering lethargy, the analyst community isn't discouraged, and their consensus price target of $ 20.55 is more than 500% above the present price.

VR Score

Informative language

Neutral language

Article tone

informal

Language

English

Language complexity

Offensive language

not offensive

Hate speech

not hateful